(:KNWN)
Business Focus: N/A
Sep 13, 2022 07:32 pm ET
Know Labs, Inc. Announces NYSE American Listing Approval
Know Labs, Inc. (OTCQB: KNWN), an emerging leader of non-invasive medical diagnostic technology, today announced that, subject to official authorization and meeting all requirements (including the price requirement) at the time of listing, the Company has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public
Sep 02, 2022 09:00 am ET
Know Labs Provides Update on IRB-Approved Internal Trial of Non-Invasive Glucose Monitoring Technology
Know Labs, Inc. (OTCQB: KNWN), an emerging developer of non-invasive medical diagnostic technology, today released a video update on the IRB-approved internal trial the Company has been conducting at its laboratory in Seattle. The video can be found
Aug 03, 2022 09:00 am ET
Know Labs Files S-1 for New Share Offering, Seeks Uplist to NYSE American Exchange
Know Labs, Inc. (OTCQB: KNWN) an emerging developer of non-invasive medical diagnostic technology, today announced it has filed a Form S-1 registration statement for a proposed new offering of 3 million shares of its common stock with an anticipated offering price of $2.00 per share. Concurrent with, and as a condition to, the offering, Know Labs wil
May 24, 2022 09:00 am ET
Know Labs Expands Leadership Team, Adds Chief Financial Officer and Chief Product Officer, As It Gets Closer to FDA Clearance Application
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostic technology, today announced the addition of two senior executives, each of whom will play a pivotal role in guiding the company toward its goal of delivering the first FDA-cleared non-invasive glucose monitor. Steven Kent joins the company as Chie
May 10, 2022 09:00 am ET
Know Labs, Inc. Discusses Significance of Patented Non-Invasive Blood Glucose Monitoring Technology with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - May 10, 2022) - The Stock Day Podcast welcomed Know Labs, Inc. (OTCQB: KNWN) ("the Company"), a company that is transforming non-invasive medical diagnostics. The company's proprietary technology, Bio-RFID™, uses radio frequency spectroscopy to capture the unique molecular signatures of analytes, such as glucose, in the bloodstream. Chairman of the Company, Ron Erickson, joined Stock Day host Everett Jolly.
Apr 05, 2022 09:00 am ET
New Foundational Patents Secure Multiple Growth Opportunities for Know Labs and Its Bio-RFID™ Non-Invasive Diagnostic Technology
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced it has been granted two new foundational patents that add significant value to its IP portfolio and proprietary Bio-RFID™ technology. The two patents protect the ability to create and utilize any database built with data captured
Mar 08, 2022 09:00 am ET
Know Labs Provides 2022 Outlook, Outlines Preparations for Pre-Submission Meeting with FDA
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today provided an update on its outlook for 2022, as the company executes its plan to bring the first FDA-cleared non-invasive glucose monitoring devices to market.
Feb 03, 2022 09:00 am ET
Know Labs Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced it has received approval from an independent Institutional Review Board (IRB) for the protocol of its upcoming internal clinical trial. This brings the company one step closer to its FDA pre-submission meeting and to launching what it believes will be the first non-invasive glucose monitoring devices.
Dec 16, 2021 09:00 am ET
Know Labs Launches Subsidiary, AI Mind Inc., Generates $4.2M in NFT Revenue to Fund Continued Non-Invasive Glucose Monitoring Device Development
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that a new subsidiary created to work with the company’s Artificial Intelligence (AI) Deep Learning Platform has generated initial revenue of approximately $4.2 million from Non-Fungible Token (NFT) sales. This revenue will be used to fund ongoing progress toward development of AI technologies for Know Labs’ non-invasive glucose monitoring devices KnowU™ and UBand™.
Oct 13, 2021 09:00 am ET
New Test Data Confirm Particle™ Bulb from Know Labs Successfully Inactivates SARS-CoV-2 Variants
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that new independent test data have confirmed the efficacy of a light bulb produced by its wholly owned subsidiary Particle, Inc., in inactivating multiple variants of SARS-CoV-2, the virus that causes COVID-19. The data are based on tests performed by Texas Biomedical Research Institute (Texas Biomed).
Oct 06, 2021 09:00 am ET
New Tests Show Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today published a new report on its non-invasive platform technology, Bio-RFIDTM, comparing its clinical accuracy to FDA-cleared glucose monitoring devices that are currently availa
Sep 22, 2021 09:00 am ET
Know Labs Expands Non-Invasive Glucose Monitoring Product Portfolio with Introduction of New KnowU™ Diagnostic Device
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today introduced the KnowU™, a new portable medical-grade glucose monitoring device that utilizes Bio-RFID™, Know Labs’ non-invasive diagnostic technology.
Jul 27, 2021 09:00 am ET
Three New Patents for Know Labs Expand IP Portfolio and Signal Further Applications for Bio-RFID™
Advancing the development of its proprietary Bio-RFIDTM platform technology while continuing to deliver against its IP strategy, Know Labs, Inc. (OTCQB: KNWN) today announced it has been granted three new patents that support its medical diagnostic focus while also signaling potential for additional non-medical applications. These new pate
Jul 14, 2021 09:00 am ET
New Patent for Know Labs Marks Latest Step Toward Commercial Launch of Bio-RFIDTM Non-Invasive Medical Diagnostic Technology
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced it has been granted another foundational patent for its Bio-RFIDTM technology. This new patent brings Know Labs portfolio to 23 issued and 34 pending patents, enhances the company’s technological leadership position and brings Know Labs one ste
Jul 08, 2021 11:20 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.
Jun 23, 2021 09:35 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.
Jun 22, 2021 09:00 am ET
Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced it has been granted an additional patent for its Bio-RFID™ technology, growing its substantial patent portfolio to 57 issued and pending patents, an important milestone for the company.
Jun 09, 2021 09:00 am ET
Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced successful results from an independent pre-clinical study validating the company’s Bio-RFID™ platform technology.
Mar 24, 2021 09:00 am ET
Know Labs Confirms Particle Bulb Kills SARS-CoV-2
Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, today shares with the public preliminary study results from Texas Biomedical Research Institute (Texas Biomed) indicating the Particle bulb’s ability to inactivate SARS-CoV-2, the virus that causes COVID-19. In
Mar 15, 2021 09:00 am ET
Know Labs Announces Close of Financing
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, announced today that it has closed on $14.2 million of financing. The financing was largely led by existing investors and insiders.
Feb 09, 2021 09:00 am ET
Know Labs Begins Process to List on Major Exchange
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, through its patented and patent pending electromagnetic energy technology platforms, announced today that it intends to list on a major national exchange, either NASDAQ or the NYSE, and is beginning the listing application process. Additionally, the Company highlighte
Dec 03, 2020 09:00 am ET
Know Labs Provides Update on Company Business, Impact of Covid-19
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced that its efforts to test and validate its patented Bio-RFID™ platform technology for non-invasive glucose monitoring with third-party research organizations have been temporarily slowed by the impact of Covid-19.
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies - Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 25, 2020 09:00 am ET
Know Labs, Inc. to Present at the LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / Know Labs, Inc. (OTCQB:KNWN), an emerging leader in non-invasive medical diagnostics, with a focus on its UBAND™ Continuous Glucose Monitor, today announced that it will be presenting at the LD 500 investor conference on Tuesday, September 1 at 1:00 PM PST / 4:00 PM EST. Know Labs Chairman and Founder, Ron Erickson, will be presenting to a live audience.
Jul 21, 2020 09:00 am ET
Know Labs Enters into Research Agreement with Mayo Clinic
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced today that it has entered into a Research Agreement with Mayo Clinic to test and validate its patented Bio-RFID™ platform technology. Know Labs plans to first deploy its Bio-RFID platform in its wearable UBAND™ as a non-invasive Continuous Glucose Monitor
Jun 02, 2020 09:00 am ET
Know Labs Raises $5.7 Million in Latest Round
Know Labs, Inc. (OTCQB: KNWN) an emerging leader in non-invasive medical diagnostics, today announced that it closed a financing round on May 26, 2020. The financing, for an aggregate of $5,739,500, was subscribed to by both new and existing accredited investors in the Company. The Company’s 8-K filing announcing the closing can be found
Apr 13, 2020 09:00 am ET
Know Labs Announces Webcast with BioPub
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, announced the publication of a webcast hosted by BioPub, a biotech investment and discussion website found at
Apr 07, 2020 09:00 am ET
Know Labs Granted Patent for its Bio-RFID™ Technology
Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that it has been granted a patent on its Bio-RFID technology. The issued patent is broad, covering the platform nature of the Bio-RFID technology and health related diagnostics employing spectroscopy in the radio/microwave frequency band.
Feb 05, 2020 09:00 am ET
Know Labs Releases Video Update
Know Labs, Inc. (OTCQB: KNWN) today released a video updating viewers on their latest progress. The link to the video can be found
Jan 29, 2020 09:00 am ET
Know Labs Formally Announces its YouTube Channel
Know Labs, Inc. (OTCQB: KNWN) today formally announced the Know Labs YouTube Channel. The Know Labs YouTube Channel can be found at:
Jan 03, 2020 09:00 am ET
Know Labs Discusses Intellectual Property Strategy
Know Labs, Inc. (OTCQB: KNWN) today reviewed its intellectual property strategy for investors as it moves into the 2020 calendar year. As discussed in its recent annual
Nov 21, 2019 09:00 am ET
Know Labs Unveils New UBAND Design and Smartphone App
Know Labs, Inc. (OTCQB: KNWN) unveiled today a first look at its wearable UBAND™ Continuous Glucose Monitor (CGM) along with its companion iPhone App.
Sep 24, 2019 09:00 am ET
Know Labs Announces Technology Webcast
Know Labs, Inc. (OTCQB: KNWN) – a creator and provider of diagnostic solutions, announced the publication of a webcast hosted by BioPub, a biotech investment discussion website found at
Sep 11, 2019 09:00 am ET
Donna Ryan Joins Know Labs Advisory Board
Know Labs, Inc. (OTCQB: KNWN) – a creator and provider of diagnostic solutions, announced today that Donna Ryan, RN, RD, MPH, CDE has joined its Medical, Scientific and Regulatory Advisory Board.
Jul 17, 2019 09:00 am ET
Know Labs Announces Significant Pre-Clinical Progress of UBAND Non-Invasive Continuous Glucose Monitor
Know Labs, Inc. (OTCQB: KNWN) – a creator of innovative medical diagnostic solutions, today announced significant progress in the development of its wearable UBAND non-invasive Continuous Glucose Monitor (CGM). Increased accuracy and precision in laboratory test subject measurements have allowed the Company to expedite its focus on an FDA-appro
Jun 20, 2019 09:00 am ET
Know Labs Expands Advisory Board
Know Labs, Inc. (OTCQB: KNWN) – a creator and provider of diagnostic solutions, announced today that Larry K. Ellingson has joined its Medical, Scientific and Regulatory Advisory Board.
May 01, 2019 09:00 am ET
Know Labs Announces Racer Technology as Manufacturing Partner
Know
Labs, Inc. (OTCQB: KNWN) a provider of diagnostic solutions, today
announced Racer
Technology Pte
Apr 23, 2019 09:00 am ET
Know Labs Announces Formation of Advisory Board
Know
Labs, Inc. (OTCQB: KNWN) – a creator and provider of diagnostic
solutions, announced today the formation of its Medical, Scientific and
Regulatory Advisory Board, the initial members of the Advisory Board and
its first meeting.
Apr 16, 2019 09:00 am ET
Mark Tapsak, Ph.D., Joins Know Labs as Vice President
Know
Labs, Inc. (OTCQB: KNWN) a provider of diagnostic solutions,
announced today that Mark Tapsak, Ph.D. has joined the Company as Vice
President, Intellectual Property.
Feb 21, 2019 09:00 am ET
Know Labs Bio-RFID™ Platform Technology Identifies Blood Alcohol Levels
Know Labs, Inc. (OTCQB:KNWN) – a provider of diagnostic solutions,
released today a video presentation of its Bio-RFID™ platform
technology’s successful identification of blood alcohol levels. In the
video presentation, CEO Phil Bosua not only discusses the Company’s use
of Bio-RFID to detect blood alcohol levels, but the broad implications
for its technology platform.
Jan 16, 2019 09:00 am ET
Know Labs Releases White Paper Detailing Experimental Results of their Bio-RFID™ Technology
Know Labs, Inc. (OTCQB: KNWN) – a provider of diagnostic solutions,
released today a white paper detailing the results of an experiment
using their Bio-RFID™ technology to detect varying blood-glucose levels
in the human body. The experiment utilized a tissue phantom mimicking a
blood/skin/muscle ratio of approximately 5%/10%/85% respectively to
measure varying amounts of glucose in the blood. The experiment produced
successful results with the sensor system showing strong signal response
and linearity between the varying glucose levels. White p
Dec 18, 2018 09:00 am ET
Know Labs CEO Phil Bosua Presents Overview of the Company’s Technology and Product Strategy
Know Labs, Inc. (OTCQB: KNWN) – a provider of diagnostic solutions,
released today a video presentation highlighting the Know Labs
non-invasive Bio-RFID™ technology and the product pathway for the
company’s UBAND™ wearable. In the video presentation Company CEO Phil
Bosua discusses the Company’s breakthrough technology, details the
product strategy for deploying the technology in to the marketplace and
addresses the significant scope of the market opportunity for Know Labs.
The presentation also highlights a comparison of the Know Labs UBAND
Dec 06, 2018 09:00 am ET
Know Labs Announces Laboratory Comparison Tests of Its UBAND Non-Invasive Blood Glucose Technology and Abbott Labs FreeStyle Libre
Know Labs, Inc. (OTCQB: KNWN), a provider of identification,
authentication and diagnostic solutions, released today a video overview
of comparison tests of the Company’s invention of its UBAND™ wearable to
detect blood glucose non-invasively and Abbott Labs FreeStyle Libre. In
the video Company CEO Phil Bosua discusses the breakthrough and
highlights a comparison of the Know Labs UBAND Bio-RFID™ technology with
an industry-leading continuous glucose monitor from Abbott Laboratories
(NYSE: ABT).
Oct 11, 2018 09:00 am ET
Know Labs Announces Bio-RFID™ Product Platform
Know Labs, Inc. (OTCQB: KNWN) – a provider of diagnostic solutions,
released today a video highlighting the Company’s product pathway and
platform. In the video CEO Phil Bosua discusses the Company’s Bio-RFID™
technological breakthrough and the plans for bringing the technology to
market.
Sep 12, 2018 09:00 am ET
James Anderson, MD, Joins Know Labs as Medical Director
Know Labs, Inc. (OTCQB: KNWN) – the developer of the calorie counter
UBAND™ wearable and its underlying non-invasive continuous glucose
monitoring technology, announced today that James Anderson, MD, has
joined the Company as Medical Director. Dr. Anderson will also serve as
Chairman of the Company’s Medical, Scientific and Regulatory Affairs
Advisory Board.
Aug 15, 2018 09:00 am ET
Know Labs Announces UBAND™ Calorie Counter Wristband
Know Labs, Inc. (OTCQB: KNWN) – a provider of identification,
authentication and diagnostic solutions, published an advertisement in
the Seattle Times newspaper today announcing its UBAND™ real time
wearable calorie counter wrist band. The first 1000 respondents to the
ad can get on the list to obtain the UBAND for $99. The Calorie Counter
UBAND is built upon the Company’s recent invention that detects blood
glucose non-invasively. We expect an automatic calorie counter to be in
demand by people who like to keep fit and maintain a healthy lifest
Aug 07, 2018 09:00 am ET
Know Labs Announces Laboratory Comparison Tests of its Non-Invasive Blood Glucose Technology and the DexCom G5®
Know Labs, Inc. (OTCQB: KNWN) – a provider of identification,
authentication and diagnostic solutions, released today a video overview
of comparison tests of the Company’s invention of a new way to detect
blood glucose non-invasively and the DexCom G5®. In the video, Company
CEO Phil Bosua discusses the breakthrough and highlights a comparison of
the Know Labs Bio-RFID™ technology with an industry leading continuous
glucose monitor from DexCom, Inc. (DXCM).
Jul 11, 2018 09:00 am ET
Know Labs Invents New Way to Detect Blood Glucose - Non-invasively
Know Labs, Inc. (f/k/a Visualant, Incorporated) (OTCQB: KNWN) – a
provider of identification, authentication and diagnostic solutions,
released today a video of the Company’s invention of a new technology to
detect blood glucose non-invasively. In the video, Company CEO Phil
Bosua briefly discusses the breakthrough.
May 30, 2018 09:00 am ET
Know Labs Appoints Michael Grabham Chief Business Officer
Know Labs, Inc. (f/k/a Visualant, Incorporated) (OTCQB: KNWN) – a
provider of identification, authentication and diagnostic solutions,
announced today that Michael Grabham has been appointed Chief Business
Officer of the Company.
May 25, 2018 09:00 am ET
Know Labs Announces Effectiveness of Name Change and New Trading Symbol
Know Labs, Inc. (f/k/a Visualant, Incorporated) (OTCQB: KNWN), a
provider of identification, authentication and diagnostic solutions,
announced today that on May 24, 2018, the Financial Industry Regulatory
Authority (“FINRA”) approved the effectiveness of a change in the
Company’s name from “Visualant, Incorporated” to “Know Labs, Inc.” and a
change in the Company’s ticker symbol from “VSUL” to the new trading
symbol “KNWN,” which became effective on the opening of trading as of
May 25, 2018. In addition, in connection with the name change and s
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.